Help the Biomedical Advanced Research and Development Authority (BARDA) fight antimicrobial resistance (AMR)! Join the workshop to learn more about BARDA, our mission, and how we plan to tackle this growing threat. The event will consist of presentations from BARDA experts, followed by a structured discussion, and Q&A.
Multi-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis. Every year, 2.8 million American develop a drug resistant infection and 35,000 people die. Globally, MDR infections kill 700,000 each year - current estimates are that MDR organisms will kill more than 10 million a year by 2050 if left unchecked.
BARDA supports development and procurement of medical countermeasures to protect Americans against chemical, biological, radiological, and nuclear (CBRN) threats. MDR does not discriminate, and victims of CBRN events are at risk of suffering fatal complications from drug resistant infections. One of BARDA’s top priorities is to develop a vaccine to protect people from these threats.
The BARDA Antibacterials program is well known for investments in small molecules since its launch in 2010, including supporting FDA approval of three antibiotics. But BARDA’s investments go beyond antibiotics. The BARDA CBRN Vaccine program has invested in efforts that led to FDA licensure of vaccines against smallpox and Ebola. And through CARB-X, the portfolio has expanded to include non-traditional products and currently supports the development of four vaccines.
Companies and others interested in working with BARDA are encouraged to attend the March 12, 2021 workshop. The event is open to the public, but space is limited. Be sure to register by March 5, 2021. Please, no more than four people from one organization.